Established Year
M² Factory Area
Global Workforce
Certified Standards
Shenzhen BioX Medical Co., Ltd. is a professional manufacturer specializing in molecular diagnostic analysis systems, genetic testing solutions, and clinical laboratory equipment. Established in 2017, the company is headquartered in Shenzhen, China, a leading center for biotechnology innovation, medical device development, and advanced manufacturing.
With a modern manufacturing facility covering more than 9,000 square meters and a workforce of over 200 employees, BioX Medical is dedicated to the research, development, production, and supply of molecular diagnostic technologies for clinical laboratories, hospitals, research institutions, public health organizations, and biotechnology companies worldwide.
Our multidisciplinary team of engineers and laboratory specialists continuously invests in product development, ensuring that our nucleic acid testing platforms and pathogen detection solutions meet the rigorous demands of modern precision medicine.
The global oncology molecular diagnostics market is undergoing a paradigm shift. As the prevalence of cancer increases globally, the demand for early-stage detection and personalized therapeutic monitoring has skyrocketed. Manufacturers and exporters in this space are no longer just equipment providers; they are strategic partners in the "War on Cancer."
Traditional tissue biopsies are being augmented by non-invasive liquid biopsies. Our molecular diagnostic systems are being optimized to detect circulating tumor DNA (ctDNA) with unprecedented sensitivity, allowing for real-time monitoring of tumor dynamics.
There is a growing trend toward moving complex genetic testing from centralized "mega-labs" to regional hospitals. Our portable and automated systems, such as the Portable Color Doppler and Integrated Diagnostic Systems, support this transition by offering lab-grade accuracy in a smaller footprint.
Raw genomic data is useless without interpretation. Modern oncology platforms are integrating AI algorithms to filter "noise" from "signals," providing clinicians with actionable reports that correlate genetic mutations with specific FDA-approved therapies.
At BioX Medical, we don't just follow industry trends; we define them. Our technological roadmap is focused on three core pillars: Automation, Accuracy, and Accessibility.
We are developing high-throughput NGS platforms that allow for the simultaneous analysis of hundreds of genes (Comprehensive Genomic Profiling). This is critical for identifying rare mutations that might respond to targeted therapies.
For absolute quantification of target DNA molecules, our digital PCR research focuses on providing sensitivity levels that can detect a single mutated cell among thousands of healthy ones—vital for minimal residual disease (MRD) monitoring.
Reducing the "Time-to-Result" is our priority. By integrating automated sample preparation (extraction) and amplification into a single cartridge, we aim to deliver molecular results in under 60 minutes.
Exporting molecular diagnostic systems requires deep knowledge of local regulatory landscapes. BioX Medical ensures that every piece of equipment meets the stringent safety and performance standards required by international health authorities.
Our products adhere to ISO 13485 quality management systems. We actively support our global partners in obtaining CE-IVD, FDA, and local MOH registrations, ensuring legal and ethical market entry.
We provide comprehensive 24/7 technical support. From remote software diagnostics to on-site training for lab technicians, we ensure that our systems operate at peak performance, minimizing laboratory downtime.
Understanding that every region has unique clinical needs, we offer flexible customization. Whether it's localized software interfaces or hardware modifications for specific environmental conditions, our Shenzhen R&D team is ready to assist.
Our systems are deployed across diverse medical settings, proving their versatility and reliability in the most demanding environments.
Scenario A: Early Screening in High-Risk Populations
Using our automated nucleic acid platforms, clinics can conduct large-scale screening for viral-associated cancers (e.g., HPV-linked cervical cancer or HBV-linked liver cancer), identifying risks long before clinical symptoms appear.
Scenario B: Intraoperative Precision
Our Advanced Surgical Imaging Systems and Diagnostic Spine Endoscopes allow surgeons to visualize tumor margins with high clarity, reducing the risk of recurrence and improving patient outcomes during complex oncological surgeries.
Scenario C: Monitoring Treatment Efficacy
For patients undergoing chemotherapy or immunotherapy, our molecular diagnostic systems track biomarker levels in blood samples. A drop in ctDNA levels provides immediate feedback to oncologists that the treatment is working, allowing for personalized dose adjustments.
Traditional pathology looks at cellular morphology (how cells look under a microscope), while molecular diagnostics look at the genetic "blueprint" (DNA/RNA) of the tumor. This allows for the identification of specific mutations (like EGFR or KRAS) that guide targeted therapy selection.
Shenzhen is the "Silicon Valley of Hardware." Sourcing from Shenzhen BioX Medical offers the benefit of a highly efficient supply chain, rapid R&D iteration, and competitive pricing without compromising on the high-tech components required for precise molecular analysis.
Most of our platforms are designed with an "Open System" philosophy, allowing laboratories to use their preferred reagent kits, though we provide optimized protocols for major global brands to ensure maximum accuracy.
Depending on the order volume and customization requirements, lead times typically range from 2 to 6 weeks. We use medical-grade global logistics to ensure temperature-sensitive components and fragile optics arrive in perfect condition.
Shenzhen BioX Medical Co., Ltd. continues to push the boundaries of clinical diagnostic science. By focusing on molecular diagnostic analysis systems and genetic testing solutions, we support the global healthcare community's move toward precision medicine. Our commitment to quality, from our 9,000sqm Shenzhen facility to our worldwide export network, ensures that laboratories everywhere have access to the reliable, scalable, and innovative technology needed for modern disease detection and clinical research.
BioX Medical
